SCHEMBL6214944

SCHEMBL6214944

O=C1Cc2cc(Nc3ncc(Br)c(NCc4ccccn4)n3)ccc2N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 16/20 1.00
PTK2B Q14289 15/20 1.00
BCL6 P41182 2/20 0.55
AURKA O14965 2/20 0.53
IGF1R P08069 2/20 0.53
FGFR1 P11362 2/20 0.53
KDR P35968 2/20 0.53
PLK4 O00444 1/20 0.53
PDPK1 O15530 1/20 0.53
DAPK3 O43293 1/20 0.53
JAK2 O60674 1/20 0.53
ROCK2 O75116 1/20 0.53
STK16 O75716 1/20 0.53
PRKD3 O94806 1/20 0.53
MAP4K4 O95819 1/20 0.53
PAK4 O96013 1/20 0.53
CHEK2 O96017 1/20 0.53
NTRK1 P04629 1/20 0.53
PRKCG P05129 1/20 0.53
INSR P06213 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6210578 0.93 PTK2 (0.86) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL6211698 0.91 PTK2 (0.84) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL6211830 0.89 PTK2 (1.00) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL6209171 0.89 PTK2 (0.80) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL6213649 0.89 PTK2 (1.00) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL6213494 0.88 PTK2 (0.78) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL3163641 0.87 PTK2 (1.00) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL6211063 0.87 PTK2 (0.79) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL6213938 0.87 PTK2 (1.00) PTK2PTK2BBCL6AURKAIGF1R
SCHEMBL6213729 0.85 PTK2 (0.73) PTK2PTK2BBCL6AURKAIGF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP claimed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US claimed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO claimed
EP-1578732-A2 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Inc. (US) 2005-09-28 EP disclosed
US-20040220177-A1 Compound for the treatment of abnormal cell growth PFIZER INC 2004-11-04 US disclosed
WO-2004056786-A2 PYRIMIDINE DERIVATES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2004-07-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220177-A1 Compound for the treatment of abnormal cell growth CCNA1, CCNB1, CCNT1 PTK2 3004/4885PTK2B 1941/4885BCL6 932/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.